Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.

Disc Medicine, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW YORK--(BUSINESS WIRE)--IRON HORSE ACQUISITION II CORP. ANNOUNCES PRICING OF $200 MILLION INITIAL PUBLIC OFFERING.

IRON HORSE ACQUISITION II CORP. ANNOUNCES PRICING OF $200 MILLION INITIAL PUBLIC OFFERING

WATERTOWN, MASS., DEC. 06, 2025 (GLOBE NEWSWIRE) -- DISC MEDICINE, INC. (NASDAQ:IRON), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF NOVEL TREATMENTS FOR PATIENTS SUFFERING FROM SERIOUS HEMATOLOGIC DISEASES, TODAY PRESENTED POSITIVE INITIAL DATA FROM THE RALLY-MF PHASE 2 TRIAL OF DISC-0974 IN ANEMIA OF MF AT THE ASH ANNUAL MEETING IN ORLANDO, FL. THE DATA DEMONSTRATED THAT TREATMENT WITH DISC-0974 RESULTED IN SUBSTANTIAL REDUCTIONS IN HEPCIDIN AND INCREASES IN IRON LEVELS TRANSLATING TO POSITIVE IMPACT ON CLINICALLY MEANINGFUL MEASURES OF ANEMIA ACROSS A BROAD RANGE OF PATIENT TYPES.

DISC MEDICINE PRESENTS POSITIVE INITIAL DATA FROM RALLY-MF PHASE 2 TRIAL IN PATIENTS WITH MYELOFIBROSIS (MF) AND ANEMIA AT THE 67TH AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING

WATERTOWN, MASS., OCT. 31, 2025 (GLOBE NEWSWIRE) -- DISC MEDICINE, INC. (NASDAQ:IRON), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF NOVEL TREATMENTS FOR PATIENTS SUFFERING FROM SERIOUS HEMATOLOGIC DISEASES, ANNOUNCED TODAY THAT COMPANY MANAGEMENT WILL PARTICIPATE IN FIRESIDE CHATS AT THREE UPCOMING INVESTOR CONFERENCES:

DISC MEDICINE TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

WATERTOWN, MASS., OCT. 21, 2025 (GLOBE NEWSWIRE) -- DISC MEDICINE, INC. (NASDAQ: IRON) (DISC), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF NOVEL TREATMENTS FOR PATIENTS SUFFERING FROM SERIOUS HEMATOLOGIC DISEASES, TODAY ANNOUNCED THE PRICING OF THE UPSIZED UNDERWRITTEN OFFERING OF SHARES OF ITS COMMON STOCK AND, IN LIEU OF COMMON STOCK TO CERTAIN INVESTORS THAT SO CHOOSE, PRE-FUNDED WARRANTS TO PURCHASE SHARES OF ITS COMMON STOCK. DISC IS SELLING 2,619,049 SHARES OF COMMON STOCK AND PRE-FUNDED WARRANTS TO PURCHASE 59,523 SHARES OF COMMON STOCK AND AI DMI LLC (THE SELLING STOCKHOLDER) IS SELLING 297,619 SHARES OF COMMON STOCK IN THE OFFERING. THE SHARES OF COMMON STOCK ARE BEING SOLD AT AN OFFERING PRICE OF $84.00 PER SHARE, AND THE PRE-FUNDED WARRANTS ARE BEING SOLD AT AN OFFERING PRICE OF $83.9999 PER PRE-FUNDED WARRANT, WHICH REPRESENTS THE PER SHARE OFFERING PRICE FOR THE COMMON STOCK LESS THE $0.0001 PER SHARE EXERCISE PRICE FOR EACH SUCH PRE-FUNDED WARRANT. THE AGGREGATE GROSS PROCEEDS TO DISC FROM THIS OFFERING ARE EXPECTED TO BE APPROXIMATELY $225 MILLION, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER OFFERING EXPENSES, EXCLUDING THE EXERCISE OF ANY PRE-FUNDED WARRANTS. THE AGGREGATE GROSS PROCEEDS TO THE SELLING STOCKHOLDER FROM THIS OFFERING ARE EXPECTED TO BE APPROXIMATELY $25 MILLION, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS. IN ADDITION, THE SELLING STOCKHOLDER HAS GRANTED THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 446,428 SHARES AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS. THE OFFERING IS EXPECTED TO CLOSE ON OCTOBER 22, 2025, SUBJECT TO THE SATISFACTION OF CUSTOMARY CLOSING CONDITIONS.

DISC MEDICINE ANNOUNCES PRICING OF $250 MILLION UPSIZED PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS

WATERTOWN, MASS., OCT. 20, 2025 (GLOBE NEWSWIRE) -- DISC MEDICINE, INC. (NASDAQ: IRON) (DISC), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF NOVEL TREATMENTS FOR PATIENTS SUFFERING FROM SERIOUS HEMATOLOGIC DISEASES, TODAY ANNOUNCED THE COMMENCEMENT OF AN UNDERWRITTEN OFFERING OF $220.0 MILLION OF SHARES OF ITS COMMON STOCK AND, IN LIEU OF COMMON STOCK TO CERTAIN INVESTORS THAT SO CHOOSE, PRE-FUNDED WARRANTS TO PURCHASE SHARES OF ITS COMMON STOCK, OF WHICH $200.0 MILLION OF SHARES ARE TO BE OFFERED BY DISC AND $20.0 MILLION OF SHARES ARE TO BE OFFERED BY AI DMI LLC (THE SELLING STOCKHOLDER). IN ADDITION, THE SELLING STOCKHOLDER INTENDS TO GRANT THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL $33.0 MILLION OF SHARES AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS. THE PROPOSED OFFERING IS SUBJECT TO MARKET AND OTHER CONDITIONS, AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE OFFERING MAY BE COMPLETED, OR AS TO THE ACTUAL SIZE OR TERMS OF THE OFFERING.

DISC MEDICINE ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS

WATERTOWN, MASS., OCT. 20, 2025 (GLOBE NEWSWIRE) -- DISC MEDICINE, INC. (NASDAQ:IRON), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF NOVEL TREATMENTS FOR PATIENTS SUFFERING FROM SERIOUS HEMATOLOGIC DISEASES, TODAY OUTLINED ITS RECENT PIPELINE AND OPERATIONAL PROGRESS AND STRATEGIC PRIORITIES FOR THE REST OF 2025 AND 2026.

DISC MEDICINE PROVIDES UPDATE ON HEMATOLOGY PORTFOLIO AND OUTLINES NEAR-TERM BUSINESS OBJECTIVES AND ANTICIPATED MILESTONES

WATERTOWN, MASS., OCT. 17, 2025 (GLOBE NEWSWIRE) -- DISC MEDICINE, INC. (NASDAQ:IRON), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF NOVEL TREATMENTS FOR PATIENTS SUFFERING FROM SERIOUS HEMATOLOGIC DISEASES, TODAY ANNOUNCED IT WILL PRESENT CLINICAL DATA AS A POSTER PRESENTATION AT THE UPCOMING 2025 AMERICAN SOCIETY OF NEPHROLOGY (ASN) KIDNEY WEEK, WHICH WILL BE HELD IN HOUSTON, TX ON NOVEMBER 6-9, 2025.

DISC MEDICINE TO PRESENT DATA FROM PHASE 1B TRIAL OF DISC-0974 IN PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD) AND ANEMIA AT 2025 AMERICAN SOCIETY OF NEPHROLOGY (ASN) KIDNEY WEEK

WATERTOWN, MASS., SEPT. 30, 2025 (GLOBE NEWSWIRE) -- DISC MEDICINE, INC. (NASDAQ:IRON), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF NOVEL TREATMENTS FOR PATIENTS SUFFERING FROM SERIOUS HEMATOLOGIC DISEASES, TODAY ANNOUNCED THE SUBMISSION OF A NEW DRUG APPLICATION (NDA) TO THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR BITOPERTIN FOR PATIENTS AGED 12 YEARS AND OLDER WITH ERYTHROPOIETIC PROTOPORPHYRIA (EPP), INCLUDING X-LINKED PROTOPORPHYRIA (XLP). DISC SUBMITTED THE NDA UNDER THE FDA'S ACCELERATED APPROVAL PATHWAY USING REDUCTION OF PROTOPORPHYRIN IX (PPIX) AS A SURROGATE ENDPOINT AND REQUESTED A PRIORITY REVIEW BASED ON BITOPERTIN'S POTENTIAL TO ADDRESS THE SIGNIFICANT UNMET NEED FOR EPP PATIENTS. BITOPERTIN HAS RECEIVED ORPHAN DRUG DESIGNATION AND RARE PEDIATRIC DISEASE DESIGNATION FROM THE FDA.

DISC MEDICINE ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION (NDA) TO US FDA FOR ACCELERATED APPROVAL OF BITOPERTIN FOR PATIENTS WITH ERYTHROPOIETIC PROTOPORPHYRIA (EPP)

WATERTOWN, MASS., JULY 14, 2025 (GLOBE NEWSWIRE) -- DISC MEDICINE, INC. (NASDAQ:IRON), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF NOVEL TREATMENTS FOR PATIENTS SUFFERING FROM SERIOUS HEMATOLOGIC DISEASES, TODAY ANNOUNCED THE APPOINTMENT OF NADIM AHMED TO ITS BOARD OF DIRECTORS. MR. AHMED IS CURRENTLY THE PRESIDENT AND CHIEF EXECUTIVE OFFICER OF CULLINAN THERAPEUTICS.

DISC MEDICINE APPOINTS NADIM AHMED TO ITS BOARD OF DIRECTORS

WATERTOWN, MASS., JUNE 12, 2025 (GLOBE NEWSWIRE) -- DISC MEDICINE, INC. (NASDAQ:IRON), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF NOVEL TREATMENTS FOR PATIENTS SUFFERING FROM SERIOUS HEMATOLOGIC DISEASES, TODAY SPOTLIGHTS 5 POSTERS PRESENTED AT THE EHA 2025 ANNUAL MEETING IN MILAN, ITALY. THIS YEAR'S PRESENTATIONS INCLUDED DATA FROM HELIOS, AN ONGOING OPEN-LABEL EXTENSION STUDY OF BITOPERTIN IN EPP, WHICH SHOWED FAVORABLE LONG-TERM EFFICACY AND SAFETY WITH SUSTAINED PROTOPORPHYRIN IX (PPIX) REDUCTIONS, IMPROVEMENT IN QUALITY OF LIFE, AND IMPROVED LIVER BIOMARKERS. DISC IS ADVANCING DEVELOPMENT AND REGISTRATIONAL ACTIVITIES FOR BITOPERTIN IN EPP, WITH PLANS TO SUBMIT AN NDA IN H2 2025. THE COMPANY HAS INITIATED APOLLO, A CONFIRMATORY CLINICAL TRIAL OF BITOPERTIN IN ADULTS AND ADOLESCENTS WITH EPP. DISC RECENTLY LAUNCHED A CAMPAIGN TO RAISE AWARENESS OF EPP AMONG PHYSICIANS, PATIENTS, AND CAREGIVERS WITH EMPHASIS ON THE CAUSATIVE ROLE OF PPIX ACCUMULATION IN THE DISEASE. LEARN MORE AT PPIXISWHY.COM.

Disc Medicine, Inc.

IRON

Price

Financial Reports

No items found.

Press Releases

Disc Medicine, Inc.

IRON.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

IRON